Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center.
Nerina DenaroEmanuela PassoniAlice IndiniGianluca NazzaroGiada Anna BeltraminiValentina BenzecryGiuseppe ColomboCarolina CauchiCinzia SolinasMario ScartozziAngelo Valerio MarzanoOrnella GarronePublished in: Vaccines (2023)
Among ultra-octogenarian patients, a clinical benefit from Cemiplimab was obtained in most, including tumor shrinkage and pain relief. Cemiplimab confirmed its effectiveness in elderly patients in a real-life setting, with no new safety concerns.
Keyphrases
- squamous cell carcinoma
- end stage renal disease
- newly diagnosed
- high resolution
- ejection fraction
- randomized controlled trial
- chronic kidney disease
- systematic review
- primary care
- chronic pain
- peritoneal dialysis
- prognostic factors
- neuropathic pain
- spinal cord injury
- mass spectrometry
- radiation therapy
- spinal cord
- patient reported